Mitochondrial toxicity is increasingly implicated in a host of drug-induced organ toxicities, including hepatotoxicity. Nefazodone was withdrawn from the US market in 2004 due to hepatotoxicity. Accordingly, we evaluated nefazodone, another triazolopyridine trazodone, plus the azaspirodecanedione buspirone, for cytotoxicity and effects on mitochondrial function. In accord with its clinical disposition, nefazodone was the most toxic compound of the three, trazodone had relatively modest effects, while buspirone showed the least toxicity. Nefazodone profoundly inhibited mitochondrial respiration in isolated rat liver mitochondria and in intact HepG2 cells where this was accompanied by simultaneous acceleration of glycolysis. Using immunocaptured OXPHOS complexes, we identified Complex 1, and to a lesser amount Complex IV, as the targets of nefazodone toxicity. No inhibition was found for trazodone, and buspirone showed 3.4-fold less inhibition of OXPHOS Complex 1 than nefazodone. In human hepatocytes that express CYP3A4, after 24 hr exposure, nefazodone and trazodone collapsed mitochondrial membrane potential, and imposed oxidative stress, as detected via glutathione depletion, leading to cell death. Our results suggest that the mitochondrial impairment imposed by nefazodone is profound and likely contributes to its hepatotoxicity, especially in patients co-treated with other drugs with mitochondrial liabilities.
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The values of OCR and ECAR reflect both the metabolic activities of the cells and the number of cells being measured. For relative measurements comparing metabolic rate after compound exposure to a pre-exposure baseline, that is, when data are expressed as a percentage of OCR or ECAR change over baseline, the number of cells present in a well does not confound analysis since the same cell population is assayed at each time interval, i.e., paired comparison design.
Measurement of Respiration in Isolated Rat Liver Mitochondria
Liver mitochondria were isolated and oxygen consumption was monitored in 96well plate format using a phosphorescent oxygen sensitive probe as previously described (Hynes et al., 2006; Will et al., 2006; Nadanaciva et al., 2007b) with minor modifications. Briefly, A65N-1 oxygen probe was reconstituted in 10.5 ml of mitochondrial incubation buffer to a concentration of approximately 100 nM. 100 µl of this solution were pipetted into each well of a 96 well plate (10 pmol of probe per well).
For drug treatments, compound stock solutions were prepared in DMSO and added to the wells to give the indicated final concentrations (final DMSO <0.5%). All drug concentrations are presented as nmol/mg of mitochondrial protein. After drug or vehicle addition, 50 µl of mitochondria stock solutions were added to each well giving the desired final concentration of mitochondria, followed by 50 µl of substrate (12.5/12.5 mM glutamate/malate/malate final concentration) without or with ADP (1.65 mM final 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60 Dykens et al., 9 3/5/2008 concentration) in incubation buffer. Finally, 100 µl of heavy mineral oil was added to each well to seal the samples from ambient oxygen, and the plate was placed in a fluorescence plate reader (Safire 2 Tecan, Innsbruck, Austria)) equilibrated at 30 o C and monitored over a period of 20 minutes measuring probe fluorescence signal in each well every 1.5 minutes in kinetic mode. Instrument settings were: 380/650nm excitation/emission, filters, a delay time of 30 µs and a measurement window of 100 µs and active temperature control of the microplate compartment at 30oC. To ensure gas and temperature equilibration of samples at the start of the assay, all the dispensing steps were carried out at 30 º C using pre-warmed solutions and a Multi-Blok ® heater (Barnstead/LabLine, Melrose Park, IL) holding the microplate. After completion of fluorescence measurements, time profiles of fluorescence intensity in each well were analyzed using Magellan® (Tecan) and Excel® (Microsoft) software, to determine the rates of oxygen consumption based on the known relationship between probe fluorescence and oxygen concentration (Will et al., 2006) . Rates of change of dissolved oxygen were subsequently determined from the slopes of these concentration profiles, over the initial 8 min.
Measurement of Activities of Individual OXPHOS Complexes
Bovine heart mitochondria were isolated according to Smith (1967) . Activities of Complex I (NADH-Ubiquinone oxidoreductase), Complex II + III (Succinatecytochrome c oxidoreductase), Complex IV (Cytochrome c oxidase), and Complex V (F 1 Fo-ATPase) were all performed as previously described (Nadanaciva et al, 2007a, b) .
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Human Hepatocyte Imaging Assay
Cryopreserved human hepatocytes were obtained commercially (CellzDirect 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  3/5/2008 the medium was changed to hepatocyte culturing medium (Williams E medium, from CellzDirect). On the 2 nd day, the Matrigel overlay was applied according to CellzDirect recommended protocol. On the 3 rd day, the cells underwent a medium change with hepatocyte culturing medium. On the 4 th day, the cells were treated overnight with the compound of interest or vehicle (0.1% DMSO). All compounds were initially solubilized in DMSO and diluted in culturing medium containing 5% fetal bovine serum to a final DMSO concentration of 0.l%. After 24 hours of incubation (37 o C, 5% CO 2 , 100% humidity), media were removed and the cells were stained by fluorescent probes in the same culturing medium lacking serum. The fluorescent probes were: tetramethyl rhodamine methyl ester for mitochondrial membrane potential (TMRM; 0.02 uM, 1hr), To capture enough cells (>500) for analysis, six image fields starting from the center of a well were collected from each well. Image analysis was performed using ImagePro Plus software (Media Cybernetics, Bethesda, MD).
Statistics
For mitochondrial respiration measurements, the slopes of O 2 consumption during the initial 8 min of the reaction were analyzed via one-way ANOVA, followed by Tukey's post hoc test (GraphPad Prism 4). For ATP depletion and isolated mitochondrial respiration assays, IC 50 values were generated using GraphPad Prism 4 or Sigma Plot. 
Results

Effect on ATP content in glucose and galactose grown HepG2 cells.
Recently we have developed a cell model where HepG2 cells are cultured in media where glucose is replaced by galactose. Under these conditions the cells are more reliant on OXPHOS, thereby becoming susceptible to mitochondrial toxicants and to drugs with known mitochondrial liabilities (Marroquin et al., 2007) . As such, these cells are better suited for assessments of drug-induced mitochondrial dysfunction. Here we evaluated Nefazodone, Buspirone and Trazodone in both cell lines to examine possible mitochondrial effects of the three compounds.
HepG2 cells grown in glucose and galactose-containing media were treated with 200uM of either nefazodone, trazodone or buspirone for 24hours ( Figure 1 ). At this concentration, nefazodone was the most toxic drug, depleting 100% of ATP in both, glucose and galactose-grown cells, trazodone showed severe toxicity in galactose-grown cells (>90% depletion), but only showed moderate toxicity (<50%) in glucose-grown cells. Buspirone was even less toxic; in galactose cells it exhibited moderate toxicity (60%) and it glucose-grown cells it exhibited no toxicity ( Figure 1 ). Due to nefazodone's detrimental effect at 200uM , we generated a full dose response curve for this compound in both glucose-and galactose-grown cells ( Figure 2 ). As already shown for trazodone and buspirone, galactose-grown cells were much more susceptible to nefazodone treatment, but at much lower concentration than with the other two drugs. The IC 50 values were 38.4µM and 9µM for glucose-and galactose-grown cells, respectively ( Figure 2 ).
The rank order of toxicity for the three compounds was therefore nefazodone > trazodone > buspirone 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 3/5/2008
Metabolic Profiling
The notion that the cytotoxicity exhibited by these molecules could be attributed to mitochondrial toxicity was further examined via simultaneously monitoring oxygen consumption and extracellular acidification rates using Seahorse BioSciences technology as described in materials and methods ( Figure 3 ). Rotenone, a potent respiratory Complex I inhibitor, was included as a positive control, and a DMSO vehicle treatment as a negative control. At 6.25uM (first injection), nefazodone profoundly inhibited oxygen consumption (OCR, Figure 3A ), accompanied by a compensatory increase in extracellular acidification rate (ECAR, Figure 3B ). These responses were worsened by the second injection, yielding 12.5uM concentration, but less of a response was noted with subsequent injections of drug. Similar, but less severe, responses were observed with trazodone and buspirone (25uM after each injection; 100µM after final injection).
In accord with the viability data of galactose-grown cells (Fig 1) , trazodone is slightly more toxic than buspirone.
Effect on Oxygen Consumption by Isolated Rat Liver Mitochondria
The higher toxicity of all compounds in galactose-grown cells, plus decreased oxygen consumption and increased acidification, strongly suggest mitochondrial inhibition as a possible mechanism of toxicity. To further test this hypothesis, the three compounds were evaluated by monitoring respiration of isolated rat liver mitochondria. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  3/5/2008 provided. At 200nmol/mg protein, nefazodone profoundly and significantly inhibited glutamate/malate driven basal State 2, and even more potently State 3, respiration ( Figure   4 ). In contrast, at the same concentration, trazodone showed a significant, but relatively modest, inhibition of State 2 respiration. Buspirone was indistinguishable from controls.
The rank order of mitochondrial impairment for the three compounds is: nefazodone >> trazodone > buspirone. Basal State 2 respiration fueled by succinate, a substrate that provides electrons to Complex II thereby bypassing Complex I, was also inhibited by nefazodone, but only at the two highest concentrations (data not shown). Such inhibition independent of Complex I suggests a second, less potent, mechanism of inhibition.
Neither trazodone nor buspirone had any effect on succinate-fueled respiration.
In light of the effect of nefazodone, dose response curves were generated for nefazodone starting at 100nmol/mg protein ( Figure 5 ). Figure 5A shows the dose dependent effect on basal respiration, whereas figure 5B corroborates the more potent effect on ADP-driven State 3 respiration noted above. The IC 50 values were 16.7 nmol/mg protein and 9.8 nmol/mg protein for glutamate/malate basal and ADP-driven respiration, respectively, and the IC 50 for basal succinate respiration is >100nmol/mg mitochondrial protein.
Target Identification
The potency of nefazodone to impair respiration fueled by glutamate/malate versus succinate suggests that Complex I could be a likely target, or perhaps adenine nucleotide translocase. Accordingly, we evaluated the effects of the drugs on the 70µM), but not by trazodone or buspirone (Figure 7 ), rendering this a likely candidate for the respiratory inhibition with succinate observed in isolated mitochondria. No complex V inhibition was observed for any of the three compounds (Table 1 ). The rank order of potency for the three drugs is: nefazodone > buspirone > trazodone.
Effects on Primary Cultures of Human Hepatocytes
The potential cytotoxic effects of the three antidepressants were tested in sandwich-cultured primary human hepatocytes for 24 hours at 100x their single-dose 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 of the mitochondrial membrane potential even in the remaining cells ( Fig. 8, third column, second row), and dramatic depletion of intracellular reduced glutathione (Fig. 8, last column, second row). Interestingly, trazodone also induced significant cell loss, mitochondrial damage, and loss of glutathione, although induction of reactive oxygen species was not observed (Fig. 8, third row) .
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Discussion
Of the three antidepressants evaluated, the data indicate that nefazodone is cytotoxic to HepG2 cells grown in either glucose or galactose, although the latter are significantly more susceptible. This was also the case for trazodone, and to a lesser extent buspirone which had only modest toxicity to glucose-grown cells. This potency rank order was corroborated via metabolic profiling and via monitoring respiration of isolated rat liver mitochondria. When respiration was fueled by succinate, inhibition by nefazodone was apparent at only the two highest concentrations, suggesting that Complex I is a primary site of inhibition, but that there is probably another mechanism of inhibition. This was confirmed using immunocaptured OXPHOS complexes, where nefazodone potently inhibited not only Complex I, but also, albeit less potently, Complex IV. In primary human hepatocytes that express CYP3A4, 24 hr exposure to nefazodone and trazodone collapses mitochondrial membrane potential, depletes glutathione and kills the cells .
In toto, the rank order of cyto-and mito-toxicity is nefazodone > trazodone > buspirone. This is in accord with the clinical disposition of these drugs, with nefazodone associated with more frequent and serious instances of hepatotoxicity (reviewed by DeSanty and Amabile, 2007) . However, this inference, although justified, must also be informed by bioavailability of the three drugs, which varies widely: at the same oral dose, Cmax of nefazodone is in a similar range as trazodone, and more than 100-fold higher than buspirone (Table 2) . Thus, tissue exposure to nefazodone can approach 10µM, rendering the cytotoxicity and other deleterious effects observed here more pathologically germane than those observed with buspirone that were primarily detected at non- 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  3/5/2008 pharmacological concentrations. This is particularly the case given the acute exposures used in some of our studies (see below). In this context, the effects of buspirone on immunocaptured respiratory Complex I may not be relevant to cytotoxicity given its lower dose and exposures in vivo (Table 2) . It is interesting to note that at both 100-fold the orally-administered single-dose human therapeutic Cmax values, both nefazodone and trazodone caused collapse of mitochondrial membrane potential, intracellular glutathione depletion, and significant cytotoxicity.
It should be noted that drug exposures in both the HepG2 and human hepatocyte studies were conducted in the presence of serum, so that potential tight protein binding appears not to limit availability. Similarly, the parent molecules (nefazodone and/or trazodone) inhibited isolated mitochondria and isolated respiratory complexes, and were cytotoxic to HepG2 cells lacking CYP3A4, and to human hepatocytes that express it Wilkening et al., 2003) . As such, metabolism by CYP3A4 is apparently not required for toxicity. Interestingly, trazodone was generally less toxic than nefazodone in all the models used here except the human hepatocytes where it was equally as toxic as nefazodone. Although admittedly a surrogate, this model more closely approximates clinical reality in that drug metabolism can occur. It bears reiteration that idiosyncratic liver injuries have been reported for trazodone (DeSanty and Amabile, 2007) , and the data from the human hepatocytes suggest that drug metabolism may contribute to such toxicity. However, because the drugs were evaluated in the human hepatocyte model at 100-fold over Cmax, trazodone was tested at a dose at least 5 times higher than in the other assays, which could account for its toxicity being more apparent in this model.
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The requirement for an elevated exposure in the in vitro setting to identify deleterious hepatic effects of these drugs may be due to a combination of: a) liver exposure to an orally-dosed drug can be an order of magnitude higher than its systemic exposure; b) population pharmacokinetic variability due to age, genetics (including metabolism), and drug-drug interactions could further exacerbate local liver exposure and toxicity; c) idiosyncratic organ history (including disease and previous drug exposures); d) onset of hepatotoxicity in vivo is typically much longer than in vitro (see below), fostering dose escalation in most in vitro systems. Indeed, even the systemic Cmax values can vary widely for nefazodone based on dose administered (Table 2 ) and patients' age groups (Barbhaiya et al., 1995) .
There is growing evidence that drugs associated with organ toxicities have disproportionate extents of mitochondrial liabilities (Wallach and Starkov, 2000; Chan et al., 2005) . For many antivirals and antibiotics, such toxicity is attributable to long-term inhibition of mitochondrial replication and gene expression (Wallace and Starkov, 2000) .
However, drugs with known organ toxicities are increasingly being found to directly inhibit and/or uncouple mitochondrial respiration (Wallace and Starkov 2000; Szewczyk and Wojtczak, 2002; Chan et al., 2005; Hynes et al., 2006; Nadanaciva et al., 2007b; Dykens et al., 2007a,b) . For example, the thiazolidinediones variously inhibit and/or uncouple mitochondrial respiration in accord with their toxicity profiles (Nadanaciva et al., 2007b) . Similarly, the rhabdomyolysis that limits the use of statins also parallels their acute and direct inhibition of mitochondrial respiration (Nadanaciva et al., 2007b) .
The model that is emerging is one where "off target" impairment of mitochondrial function precipitates cytotoxicity once a bioenergetic threshold is crossed (Boelsterli, Page 20 of 44 Toxicological Sciences   1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  3 /5/2008 2003 Wallace and Starkov, 2000; Nadanaciva et al., 2007b; Dykens et al., 2007a,b) .
Most cells have robust energetic reserves, and can accelerate ATP production in response to a host of normal or noxious stimuli. That ability to respond to stressors is gradually eroded by drugs that impair mitochondrial function until a point where the cell can no longer generate the ATP needed for survival, and it dies. It should be noted in this context that many drugs induce elevations of serum alanine aminotransferase (ALT), a direct reflection of hepatocellular death, and many of these drugs have mitochondrial liabilities (Boelsterli, 2003; Dykens et al., 2007a) .
In this model of drug toxicity via mitochondrial dysfunction, the deleterious effects on mitochondria are likely a fixed value, occurring in most patients to the same extent. The factors that contribute to idiosyncratic susceptibility are organ history and capacity to compensate for loss of mitochondrial capacity, which in turn has a genetic basis dictated by both the nuclear and mitochondrial genomes. Estimates of mitochondrial half-lives vary, but mitochondrial replacement occurs on a time scale of days-to-weeks. Given this time scale, even mild drug-induced mitochondrial impairment can gradually accumulate, amplifying the deleterious consequences of acute drug exposure. It bears reiteration that the time scales and drug concentrations used in our models reflect experimental expediency much more than the realities of pathophysiology.
For example, cytotoxicity was assessed only after 24hr exposures, and it is feasible that longer exposures at lower doses could have exacerbated toxicity. Moreover, many drugs can be bio-accumulated by transmembrane carriers at the plasma membrane and at the mitochondrial membranes. For example, the statins paradoxically induce apoptosis in anaerobically-poised, fast-twitch fibers, and not in mitochondrially-enriched slow-twitch 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  3/5/2008 fibers, because of a selective membrane transporter on the susceptible fibers that takes up the statin (Westwood et al., 2005; Dykens et al., 2007b) . Indeed, cations can also bioaccumulate into the mitochondrial matrix because of the strong (approx. 220mV) mitochondrial membrane potential, further exacerbating deleterious consequences (Dykens et al., 2007a,b) .
In addition to the bioenergetic threshold, drug-induced mitochondrial impairment can yield toxicity via other routes. For example, respiratory impairment increases the time the various OXPHOS remain in the reduced state, correspondingly increasing the probability of untoward autoxidation and univalent O 2 reduction to yield superoxide and other reactive oxygen or nitrogen species (ROS, RNS) (Brown and Borutaite, 2007) .
Similarly, under some conditions, uncoupling can also increase mitochondrial ROS formation (Dykens 1994). In our models, depending on the time scales, such increased free radical formation is detected directly, but also secondarily via glutathione depletion which serves as a longer-term index of cellular redox status. The known idiosyncratic hepatotoxin troglitazone very potently impairs mitochondrial respiration (Nadanaciva et al., 2007b; Dykens et al., 2007b) , but hepatotoxicity is not apparent in pre-clinical animal models. Only when the mitochondrial form of superoxide dismutase is knocked down by 50% is the hepatoxicity of troglitazone revealed in vivo (Ong et al., 2005) . In this light, organ toxicity with a mitochondrial etiology is also a consequence of the equilibrium between radical formation and antioxidant capacity. In this case, however, the threshold is the antioxidant status of the cell.
Of course, the bioenergetic and antioxidant thresholds are metabolically and genetically connected, but they illustrate that drug-induced mitochondrial impairment can 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  3/5/2008 injure and kill cells in a myriad of ways. And they also underscore the importance of mitochondrial assessments in pre-clinical drug development programs, and the need for more models that better predict potential organ toxicity earlier in the drug development process.
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Figure 2:
HepG2 cells grown in either glucose ( ) or galactose ( )media were incubated with the indicated concentrations of nefazodone. As reflected by the left shift in the curve, galactose-grown cells were significantly more susceptible to nefazodone treatment (IC 50 = 8.98µM) compared to cells grown in glucose media (IC 50 = 38.40µM). Data are mean ± SD (n=3).
Figure 3:
Metabolic Profiling reveals a decrease in oxygen consumption (OCR) upon exposure to nefazodone, trazodone, buspirone (Panel A; rotenone is a positive control, and DMSO is vehicle control). This is accompanied by an increase in acidification rate (ECAR) as glycolysis accelerates to compensate for reduced respiration (Panel B). Data are collected simultaneously, and nefazodone, trazodone, buspirone and rotenone were injected to 6.25µM, 25 µM, 25µM, and 1.25 µM final concentrations, respectively, at each of the time points A, B, C and D. For example, after 4 injections, cells are exposed to 25µM nefazodone. 1  2  3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59 60 3/5/2008 significant differences between treatment groups as analyzed by ANOVA. Data are mean ± SE (n=7).
Figure 5
Nefazodone inhibits basal and ADP-stimulated respiration in isolated liver mitochondria in a dose depend matter. Cmax (see Table 2 ) and stained with DRAQ5 for nuclei and intracellular lipids (first column), CM-H 2 DCFDA for reactive oxygen species (second column), TMRM for mitochondrial membrane potential (third column), and mBCl for intracellular glutathione (fourth column). The images from each row are obtained from the same image field of the same treatment sample.
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